Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 0.69 |
| ▸ | HTR1A | P08908 | 8/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.51 |
| ▸ | HTR3B | O95264 | 2/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7863587 | 0.83 | HTR3E (0.56) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL28469016 | 0.83 | ADRB1 (0.56) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL13118662 | 0.82 | HTR7 (0.69) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL1914606 | 0.80 | HTR7 (1.00) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL30022113 | 0.80 | HTR7 (1.00) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL26181132 | 0.79 | HTR7 (0.61) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL30146627 | 0.79 | HTR7 (0.96) | HTR7HTR1AADRB1HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL6786785 | 0.79 | HTR7 (0.96) | HTR7HTR1AADRB1HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL29157433 | 0.79 | HTR7 (0.96) | HTR7HTR1AADRB1HTR3EHTR3B | |
| SCHEMBL15743325 | 0.78 | HTR7 (1.00) | HTR7HTR1AADRB1HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705002-B2 | Biaryls useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080090837-A1 | Na channel and Ca channel antagonists; potentiation; side effects reduction; pains, epilepsy, neurodegenerative disorders, psychiatric disorders,movement disorders, neuroendocrine disorders etc.; 2-hydroxy-1-[4-[3-(2-hydroxyphenyl)phenyl]piperazin-1-yl]-4-methyl-pentan-1-one; | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090837-A1 | Na channel and Ca channel antagonists; potentiation; side effects reduction; pains, epilepsy, neurodegenerative disorders, psychiatric disorders,movement disorders, neuroendocrine disorders etc.; 2-hydroxy-1-[4-[3-(2-hydroxyphenyl)phenyl]piperazin-1-yl]-4-methyl-pentan-1-one; | CACNA1B, SCN1A, CACNA1S | HTR7 317/4885HTR1A 84/4885ADRB1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.